|
1
|
Khoury MA, Bahsoun MA, Fadhel A, Shunbuli S, Venkatesh S, Ghazvanchahi A, Mitha S, Chan K, Fornazzari LR, Churchill NW, Ismail Z, Munoz DG, Schweizer TA, Moody AR, Fischer CE, Khademi A. Delusional Severity Is Associated with Abnormal Texture in FLAIR MRI. Brain Sci 2022; 12:600. [PMID: 35624987 PMCID: PMC9139341 DOI: 10.3390/brainsci12050600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 04/27/2022] [Indexed: 02/04/2023] Open
Abstract
Background: This study examines the relationship between delusional severity in cognitively impaired adults with automatically computed volume and texture biomarkers from the Normal Appearing Brain Matter (NABM) in FLAIR MRI. Methods: Patients with mild cognitive impairment (MCI, n = 24) and Alzheimer’s Disease (AD, n = 18) with delusions of varying severities based on Neuropsychiatric Inventory-Questionnaire (NPI-Q) (1—mild, 2—moderate, 3—severe) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were analyzed for this task. The NABM region, which is gray matter (GM) and white matter (WM) combined, was automatically segmented in FLAIR MRI volumes with intensity standardization and thresholding. Three imaging biomarkers were computed from this region, including NABM volume and two texture markers called “Integrity” and “Damage”. Together, these imaging biomarkers quantify structural changes in brain volume, microstructural integrity and tissue damage. Multivariable regression was used to investigate relationships between imaging biomarkers and delusional severities (1, 2 and 3). Sex, age, education, APOE4 and baseline cerebrospinal fluid (CSF) tau were included as co-variates. Results: Biomarkers were extracted from a total of 42 participants with longitudinal time points representing 164 imaging volumes. Significant associations were found for all three NABM biomarkers between delusion level 3 and level 1. Integrity was also sensitive enough to show differences between delusion level 1 and delusion level 2. A significant specified interaction was noted with severe delusions (level 3) and CSF tau for all imaging biomarkers (p < 0.01). APOE4 homozygotes were also significantly related to the biomarkers. Conclusion: Cognitively impaired older adults with more severe delusions have greater global brain disease burden in the WM and GM combined (NABM) as measured using FLAIR MRI. Relative to patients with mild delusions, tissue degeneration in the NABM was more pronounced in subjects with higher delusional symptoms, with a significant association with CSF tau. Future studies are required to establish potential tau-associated mechanisms of increased delusional severity.
Collapse
Affiliation(s)
- Marc A. Khoury
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
| | - Mohamad-Ali Bahsoun
- Institute for Biomedical Engineering, Science & Tech (iBEST), a Partnership between St. Michael’s Hospital and Ryerson University, Toronto, ON M5V 1T8, Canada; (M.-A.B.); (A.G.); (S.M.); (K.C.)
- Electrical, Computer and Biomedical Engineering Department, Ryerson University, Toronto, ON M5B 2K3, Canada
| | - Ayad Fadhel
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
| | - Shukrullah Shunbuli
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
| | - Saanika Venkatesh
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
- Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada
| | - Abdollah Ghazvanchahi
- Institute for Biomedical Engineering, Science & Tech (iBEST), a Partnership between St. Michael’s Hospital and Ryerson University, Toronto, ON M5V 1T8, Canada; (M.-A.B.); (A.G.); (S.M.); (K.C.)
- Electrical, Computer and Biomedical Engineering Department, Ryerson University, Toronto, ON M5B 2K3, Canada
| | - Samir Mitha
- Institute for Biomedical Engineering, Science & Tech (iBEST), a Partnership between St. Michael’s Hospital and Ryerson University, Toronto, ON M5V 1T8, Canada; (M.-A.B.); (A.G.); (S.M.); (K.C.)
- Electrical, Computer and Biomedical Engineering Department, Ryerson University, Toronto, ON M5B 2K3, Canada
| | - Karissa Chan
- Institute for Biomedical Engineering, Science & Tech (iBEST), a Partnership between St. Michael’s Hospital and Ryerson University, Toronto, ON M5V 1T8, Canada; (M.-A.B.); (A.G.); (S.M.); (K.C.)
- Electrical, Computer and Biomedical Engineering Department, Ryerson University, Toronto, ON M5B 2K3, Canada
| | - Luis R. Fornazzari
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
- Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada
| | - Nathan W. Churchill
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
- Institute of Medical Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Zahinoor Ismail
- Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 4N1, Canada;
| | - David G. Munoz
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Tom A. Schweizer
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
- Institute for Biomedical Engineering, Science & Tech (iBEST), a Partnership between St. Michael’s Hospital and Ryerson University, Toronto, ON M5V 1T8, Canada; (M.-A.B.); (A.G.); (S.M.); (K.C.)
- Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada
- Division of Neurosurgery, Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON M5T 1P5, Canada
| | - Alan R. Moody
- Department of Medical Imaging, University of Toronto, Toronto, ON M5T 1W7, Canada;
| | - Corinne E. Fischer
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
- Institute of Medical Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada
- Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, ON M5T 1R8, Canada
| | - April Khademi
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Toronto, ON M5V 1T8, Canada; (M.A.K.); (A.F.); (S.S.); (S.V.); (L.R.F.); (N.W.C.); (D.G.M.); (T.A.S.); (A.K.)
- Institute for Biomedical Engineering, Science & Tech (iBEST), a Partnership between St. Michael’s Hospital and Ryerson University, Toronto, ON M5V 1T8, Canada; (M.-A.B.); (A.G.); (S.M.); (K.C.)
- Electrical, Computer and Biomedical Engineering Department, Ryerson University, Toronto, ON M5B 2K3, Canada
| |
Collapse
|